Dr Reddy's to now sell Novartis top brand Voveran

Hyderabad: Drugmaker, Dr. Reddy's Laboratories Ltd., has recently announced that the company has entered into an exclusive sales and distribution agreement with Novartis India Limited (NIL) for the Voveran range, the Calcium range and Methergine in India.

Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute the well-established Voveran range, the Calcium range and Methergine in India.

"The company will use its strengths in promotion and distribution to considerably expand its engagement with healthcare professionals with the aim of enabling access to patients in need," Dr. Reddy's Labs stated.

Barring unforeseen circumstances, this has the potential to drive value for shareholders of NIL. Novartis AG will retain Trademark ownership of these medicines.

Read also: Dr Reddys in S&P Global Sustainability Yearbook for 2nd Year

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), said: "We are delighted to enter into this arrangement with NIL to promote and distribute these well-established brands that are trusted by patients and healthcare professionals. Our India business has been a strong growth driver and remains a key focus market for us. This arrangement will strengthen our portfolio in the pain management and women's health areas. It is our endeavour to build on the legacy created by NIL over the years and we intend to evaluate capabilities to maintain business continuity. This will help accelerate access and reach more patients in keeping with our purpose of 'Good Health Can't Wait."

Sanjay Murdeshwar, Country President and Managing Director, Novartis in India, said, "Today, on one hand, keeping the patient interest at the center, we have entered this strategic business arrangement with Dr. Reddy's Laboratories to extend access to our Established Medicines to benefit more patients in India efficiently. On the other hand, we understand the implication on the roles of our colleagues in Novartis India Limited and are doing our best to support them."

About Novartis' philosophy of collaborating with stakeholders in the healthcare ecosystem, Sanjay says, "We are committed to working with organizations that resonate with our purpose of improving and extending people's lives. To that end, we collaborate with entities such as the government, patient organizations, start-ups, industry associations, healthcare providers, pharmaceutical companies amongst others, who are working towards reducing barriers in the journey of a patient ranging from awareness, diagnosis, access and adherence."

Read also: Dr Reddys unveils generic version of Vasostrict vials in US